Biomarkers in ex vivo lung perfusion (evlp) perfusate
AssigneeUniversity Health Network
InventorsSHAFIQUE KESHAVJEE, MINGYAO LIU, MARCELO CYPEL, ANDREW SAGE
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity Health Network
InventorsSHAFIQUE KESHAVJEE, MINGYAO LIU, MARCELO CYPEL, ANDREW SAGE
Estimating the term…
Methods and kits for screening, diagnosing, detecting or predicting a patient outcome/risk variable for a lung transplant recipient after transplant or an EVLP outcome by measuring biomarker levels of one or more biomarkers selected from IL-6, IL-8, sTNFR1 and sTREM-1 in EVLP perfusate are described. The methods involve for example, i. obtaining one or more test EVLP perfusate samples of a donor lung; ii. determining in one or more test EVLP perfusate sample of a donor lung, a polypeptide level of one or more biomarkers selected from IL-8, IL-6, sTNFR1 and sTREM-1; and iii. a) comparing the polypeptide level of the one or more biomarkers in the perfusate sample with a control or cut-off level, wherein the differential level is indicative of outcome/risk of after transplant or of an EVLP outcome; or b) using the polypeptide level of one or several of the one or more biomarkers in combination, as part of an algebraic calculation of outcome/risk.
A method for the screening, diagnosing, or detecting of outcome/risk as it relates to donor lungs, comprising:
-4. (canceled)
-11. (canceled)
(canceled)
A method for the early detection of donor lungs that will be declined at the end of the EVLP process comprising:
A method of selecting a candidate donor lung for transplant, the method comprising:
-32. (canceled)
-36. (canceled)
-44. (canceled)
(canceled)
Dependencies are inferred from the claim text.